ES2187670T3 - Utilizacion de ciclodextrinas para modular la expresion genica con una respuesta inmunoestimuladora reducida. - Google Patents

Utilizacion de ciclodextrinas para modular la expresion genica con una respuesta inmunoestimuladora reducida.

Info

Publication number
ES2187670T3
ES2187670T3 ES96928899T ES96928899T ES2187670T3 ES 2187670 T3 ES2187670 T3 ES 2187670T3 ES 96928899 T ES96928899 T ES 96928899T ES 96928899 T ES96928899 T ES 96928899T ES 2187670 T3 ES2187670 T3 ES 2187670T3
Authority
ES
Spain
Prior art keywords
cyclodextrines
gene expression
modulate gene
immunostimulatory response
reduced immunostimulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96928899T
Other languages
English (en)
Inventor
Qiuyan Zhao
Jamal Temsamani
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Application granted granted Critical
Publication of ES2187670T3 publication Critical patent/ES2187670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION APORTA UN METODO PARA REDUCIR LOS EFECTOS INMUNOESTIMULADORES DE CIERTOS FOSFORTIOATO OLIGONUCLEOTIDOS USADOS PARA TRATAR ESTADOS DE ENFERMEDAD MEDIADOS POR PATOGENOS Y OTRAS SITUACIONES MEDICAS. LOS EFECTOS INMUNOESTIMULADORES DE LOS FOSFOROTIOATO OLIGONUCLEOTIDOS SE REDUCEN DE ACUERDO CON EL METODO DE LA INVENCION MEDIANTE LA ADMINISTRACION DE FOSFOROTIOATO OLIGONUCLEOTIDOS EN UNA FORMULACION TERAPEUTICA QUE INCLUYE AL MENOS UNA CICLODEXTRINA A UN MAMIFERO AFLIGIDO CON LA ENFERMEDAD O CONDICION QUE ESTA SIENDO TRATADA. LA RESPUESTA INMUNE DEL MAMIFERO SE MONITORIZA TAMBIEN CON EL METODO DE LA INVENCION.
ES96928899T 1995-09-12 1996-08-19 Utilizacion de ciclodextrinas para modular la expresion genica con una respuesta inmunoestimuladora reducida. Expired - Lifetime ES2187670T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/527,126 US6667293B1 (en) 1995-09-12 1995-09-12 Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response

Publications (1)

Publication Number Publication Date
ES2187670T3 true ES2187670T3 (es) 2003-06-16

Family

ID=24100201

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96928899T Expired - Lifetime ES2187670T3 (es) 1995-09-12 1996-08-19 Utilizacion de ciclodextrinas para modular la expresion genica con una respuesta inmunoestimuladora reducida.

Country Status (10)

Country Link
US (2) US6667293B1 (es)
EP (1) EP0850070B1 (es)
JP (1) JPH11512426A (es)
AT (1) ATE231398T1 (es)
AU (1) AU6848596A (es)
CA (1) CA2231687A1 (es)
DE (1) DE69625919T2 (es)
DK (1) DK0850070T3 (es)
ES (1) ES2187670T3 (es)
WO (1) WO1997010005A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6667293B1 (en) * 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
JP2003507345A (ja) * 1999-08-10 2003-02-25 エムエル ラボラトリーズ ピーエルシー デキストリン溶液を使用した治療薬剤の送達方法
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
US6624358B2 (en) * 2001-12-13 2003-09-23 Andrew Corporation Miniature RF coaxial cable with corrugated outer conductor
ES2377318T3 (es) 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
KR20050051686A (ko) * 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
US9572895B2 (en) 2010-08-06 2017-02-21 The Board Of Trustees Of The University Of Illinois Multiplexed supramolecular assemblies for non-viral delivery of genetic material
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5691316A (en) * 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US6667293B1 (en) * 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response

Also Published As

Publication number Publication date
US6667293B1 (en) 2003-12-23
ATE231398T1 (de) 2003-02-15
DK0850070T3 (da) 2003-04-22
CA2231687A1 (en) 1997-03-20
DE69625919T2 (de) 2004-01-15
WO1997010005A2 (en) 1997-03-20
AU6848596A (en) 1997-04-01
WO1997010005A3 (en) 1997-06-26
EP0850070B1 (en) 2003-01-22
EP0850070A2 (en) 1998-07-01
DE69625919D1 (de) 2003-02-27
US20030148981A1 (en) 2003-08-07
JPH11512426A (ja) 1999-10-26

Similar Documents

Publication Publication Date Title
ES2141516T3 (es) Metodo para modular la expresion de genes con respuesta inmunoestimuladora reducida.
PT928335E (pt) Metodo de utilizacao de oligonucleotidos contendo dinucleosidos cpg modificados
GR3020557T3 (en) Oligonucleotide alkylphosphonates and alkylphosphonothioates.
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
ES2187670T3 (es) Utilizacion de ciclodextrinas para modular la expresion genica con una respuesta inmunoestimuladora reducida.
BR9815357A (pt) Composição farmacêutica, processos de prevenir ou tratar uma doença, de prevenir ou tratar a doença de alzheimer em um paciente, de avaliar a eficácia de um processo de tratamento de alzheimer em um paciente, de monitorar a doença de alzheimer ou a suscetibilidade a esta em um paciente, uso de peptìdeo a * ou um anticorpo deste, composição, e, conjunto de diagnósticos para a monitoração do tratamento da doença de alzheimer
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
BR9407560A (pt) Copolimeros elastômeros termoplásticos enxertados com silicone e composiçoes para tratamento dos cabelos e da pele contendo estes copolimeros
NO306808B1 (no) Anvendelse av mannosefosfater for behandling av fibrotiske sykdommer
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
EP0744176A3 (en) Methods for inhibiting bone loss
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
BR9611033A (pt) Processos para tratar infecção por h.pylori, em um mamífero e para converter a forma coccóide de h. pylori em cultura na forma em espiral e a forma em espiral de h.pylori em cultura na forma coccóide, formulação farmaceutica e uso de um agente capaz de induzir a forma coccóide de h.pylori
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
EA200000643A1 (ru) Способ нейтрализации свободных радикалов в тканях организма человека
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту
UA19596A (uk) Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору
ECSP951424A (es) Procedimiento para la administracion de azitromicina
UA30460A (uk) Спосіб лікування системного аутоімунного захворювання
UA32111A (uk) Спосіб одержання препарату для лікування захворювань опорно-рухового апарату